DiaMedica Therapeutics Inc. (DMAC)
Last updated: 2026-10-21 21:07:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
DiaMedica Therapeutics Inc. (DMAC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.71, with a market capitalization of $424.40M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.25 to $10.42. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$424.40M | |
$8.72 | |
$10.88 | |
$1.12 | |
$8.67 | |
138.72K | |
183.21K | |
-- | |
$10.42 | |
$5.25 | |
-- | |
-- |
DiaMedica Therapeutics Inc. (DMAC) After-Hours Stock Price
DiaMedica Therapeutics Inc. (DMAC) is trading at $8.68 in after-hours trading as of 2026-10-21 19:56:52, up 0.12% ($0.01) from the regular-session close of $8.67.
After-hours trading shows how investors are pricing DMAC after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
DiaMedica Therapeutics Inc. (DMAC) 7-Day Stock Price Change
Over the past seven days, DiaMedica Therapeutics Inc. (DMAC) moved from $8.20 to $8.71, representing a gain of 6.16% ($0.51).
The stock traded between $7.53 and $8.88 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 235.72 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
DMAC 52-Week Price Position
Position in Range: 66.9%
DMAC is currently trading at $8.71, placing it 66.9% of the way from its 52-week low of $5.25 to its 52-week high of $10.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is DiaMedica Therapeutics Inc. (DMAC)?
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
DiaMedica Therapeutics Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 35 |
| Exchange | NASDAQ |
| Company Website |
How to Buy DiaMedica Therapeutics Inc. (DMAC) Stock on MEXC
Eligible investors can buy real shares of DiaMedica Therapeutics Inc. (DMAC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is DiaMedica Therapeutics Inc. (DMAC) stock price today?
2.Is DMAC stock going up or down today?
3.What is DMAC pre-market price?
4.What is DMAC after-hours price?
5.Is DMAC stock trading now?
6.Where does DMAC sit relative to its 52-week high and low?
7.What sector is DiaMedica Therapeutics Inc. in?
8.What is DiaMedica Therapeutics Inc.'s market capitalization and where is it listed?
9.How is DMAC valued in terms of P/E ratio and EPS?
10.Does DiaMedica Therapeutics Inc. pay a dividend?
Explore More US Stocks
Search Stocks
DMAC Stock Calculator
Estimate the value between DMAC shares and USD.
DMAC Shares to USD
1.00 DMAC shares = 8.705 USD
Calculations are estimates based on the latest available price and are for reference only.


